SCHEMBL1223604

SCHEMBL1223604

CCCCCCCCCCCCCCCCNC(CO)(CO)CO

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 9/20 0.44
LMNA P02545 2/20 0.42
ALDH1A1 P00352 2/20 0.42
TSHR P16473 2/20 0.42
HSD17B10 Q99714 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
NAAA Q02083 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
ADH1B P00325 1/20 0.39
ADH1C P00326 1/20 0.39
ADH1A P07327 1/20 0.39
ADH4 P08319 1/20 0.39
ADH7 P40394 1/20 0.39
GBA1 P04062 2/20 0.39
CASP2 P42575 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1221879 1.00 EPHX1 (0.44) EPHX1LMNAALDH1A1TSHRHSD17B10
SCHEMBL1222080 1.00 EPHX1 (0.44) EPHX1LMNAALDH1A1TSHRHSD17B10
SCHEMBL12858918 1.00 EPHX1 (0.44) EPHX1LMNAALDH1A1TSHRHSD17B10
SCHEMBL6013242 1.00 EPHX1 (0.44) EPHX1LMNAALDH1A1TSHRHSD17B10
SCHEMBL1223539 1.00 EPHX1 (0.44) EPHX1LMNAALDH1A1TSHRHSD17B10
Bromide SCHEMBL8935087 0.98 EPHX1 (0.42) EPHX1LMNAALDH1A1TSHRHSD17B10
Hydrochloric Acid SCHEMBL27090275 0.98 EPHX1 (0.42) EPHX1LMNAALDH1A1TSHRHSD17B10
Hydrochloric Acid SCHEMBL10615875 0.98 EPHX1 (0.42) EPHX1LMNAALDH1A1TSHRHSD17B10
SCHEMBL7857838 0.98 ALDH1A1 (0.43) EPHX1LMNAALDH1A1TSHRHSD17B10
SCHEMBL24103917 0.91 EPHX1 (0.41) EPHX1LMNAALDH1A1TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2217560-B1 SYNTHETIC ANALOGS OF SPHINGOLIPIDS YISSUM RES DEV CO (IL) 2016-01-27 EP claimed
US-20110034542-A1 NOVEL SYNTHETIC ANALOGS OF SPHINGOLIPIDS HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) 2011-02-10 US claimed
EP-2217560-A1 NOVEL SYNTHETIC ANALOGS OF SPHINGOLIPIDS Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. (IL) 2010-08-18 EP claimed
WO-2009060457-A1 NOVEL SYNTHETIC ANALOGS OF SPHINGOLIPIDS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2009-05-14 WO claimed
EP-3229811-B1 PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS GRI BIO INC (US) 2021-02-24 EP disclosed
WO-2016094226-A1 PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS GLYCOREGIMMUNE, INC. (US) 2016-06-16 WO disclosed
US-20160158258-A1 PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS ALTIUM GROWTH FUND, LP 2016-06-09 US disclosed
US-9340488-B2 Synthetic analogs of sphingolipids HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) 2016-05-17 US disclosed
US-9340488-B2 Synthetic analogs of sphingolipids HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) 2016-05-17 US disclosed
EP-2217560-B1 SYNTHETIC ANALOGS OF SPHINGOLIPIDS YISSUM RES DEV CO (IL) 2016-01-27 EP disclosed
US-20150073003-A1 NOVEL SYNTHETIC ANALOGS OF SPHINGOLIPIDS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2015-03-12 US disclosed
US-20150073003-A1 NOVEL SYNTHETIC ANALOGS OF SPHINGOLIPIDS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2015-03-12 US disclosed
US-8962891-B2 Synthetic analogs of sphingolipids HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) 2015-02-24 US disclosed
US-8962891-B2 Synthetic analogs of sphingolipids HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) 2015-02-24 US disclosed
US-20110034542-A1 NOVEL SYNTHETIC ANALOGS OF SPHINGOLIPIDS HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) 2011-02-10 US disclosed
US-20110034542-A1 NOVEL SYNTHETIC ANALOGS OF SPHINGOLIPIDS HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) 2011-02-10 US disclosed
US-20110028719-A1 SCREENING METHODS FOR AMYLOID BETA MODULATORS WARATAH PHARMACEUTICALS INC. (CA) 2011-02-03 US disclosed
US-20110028719-A1 SCREENING METHODS FOR AMYLOID BETA MODULATORS WARATAH PHARMACEUTICALS INC. (CA) 2011-02-03 US disclosed
EP-2217560-A1 NOVEL SYNTHETIC ANALOGS OF SPHINGOLIPIDS Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. (IL) 2010-08-18 EP disclosed
WO-2009060457-A1 NOVEL SYNTHETIC ANALOGS OF SPHINGOLIPIDS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2009-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028719-A1 SCREENING METHODS FOR AMYLOID BETA MODULATORS APP, BACE1, IAPP EPHX1 2529/4885LMNA 1372/4885ALDH1A1 4135/4885
US-20160158258-A1 PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS RXRA, RXRG, CX3CR1 EPHX1 1570/4885LMNA 2135/4885ALDH1A1 999/4885
US-20150073003-A1 NOVEL SYNTHETIC ANALOGS OF SPHINGOLIPIDS CERS2, SGMS2, SGMS1 EPHX1 1730/4885LMNA 2702/4885ALDH1A1 3648/4885
US-20110034542-A1 NOVEL SYNTHETIC ANALOGS OF SPHINGOLIPIDS CERS2, SGMS2, SGMS1 EPHX1 1730/4885LMNA 2702/4885ALDH1A1 3648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.